• Je něco špatně v tomto záznamu ?

Analysis of the integration of human papillomaviruses in head and neck tumours in relation to patients' prognosis

Z. Vojtechova, I. Sabol, M. Salakova, L. Turek, M. Grega, J. Smahelova, O. Vencalek, E. Lukesova, J. Klozar, R. Tachezy,

. 2016 ; 138 (2) : 386-95. [pub] 20150813

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc16020445

Integration, which leads to the disruption of the circular HPV genome, is considered as a critical, albeit not obligatory, step in carcinogenic progression. Although cervical carcinomas with extrachromosomal HPV plasmid genomes have been described, the virus is integrated in 70% of HPV16-positive cervical tumours. Limited information is available about HPV integration in head and neck tumours (HNC). In this study, we have characterised the physical status of HPV in a set of tonsillar tumour samples using different methods--the mapping of E2 integration breakpoint at the mRNA level, the 3' RACE based Amplification of Papillomavirus Oncogene Transcripts (APOT) assay and Southern blot. Furthermore, the impact of HPV integration on patients' prognosis has been evaluated in a larger set of 186 patients with head and neck cancer. Based on the analysis of E2 mRNA, HPV was integrated in the host genome in 43% of the HPV-positive samples. Extrachromosomal or mixed form was present in 57%. In fresh frozen samples, the APOT and E2 mapping results were in agreement. The results were confirmed using Southern blotting. Furthermore, the type and exact site of integration were determined. The survival analysis of 186 patients revealed HPV positivity, tumour size and lymph node positivity as factors that influence disease specific survival. However, no statistically significant difference was found in disease specific survival between patients with HPV-positive integrated vs. extrachromosomal/mixed forms of the virus.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc16020445
003      
CZ-PrNML
005      
20170111105720.0
007      
ta
008      
160722s2016 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1002/ijc.29712 $2 doi
024    7_
$a 10.1002/ijc.29712 $2 doi
035    __
$a (PubMed)26239888
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Vojtechova, Zuzana $u Department of Immunology, Institute of Hematology and Blood Transfusion, Prague, Czech Republic. Department of Genetics and Microbiology, Faculty of Science, Charles University in Prague, Czech Republic.
245    10
$a Analysis of the integration of human papillomaviruses in head and neck tumours in relation to patients' prognosis / $c Z. Vojtechova, I. Sabol, M. Salakova, L. Turek, M. Grega, J. Smahelova, O. Vencalek, E. Lukesova, J. Klozar, R. Tachezy,
520    9_
$a Integration, which leads to the disruption of the circular HPV genome, is considered as a critical, albeit not obligatory, step in carcinogenic progression. Although cervical carcinomas with extrachromosomal HPV plasmid genomes have been described, the virus is integrated in 70% of HPV16-positive cervical tumours. Limited information is available about HPV integration in head and neck tumours (HNC). In this study, we have characterised the physical status of HPV in a set of tonsillar tumour samples using different methods--the mapping of E2 integration breakpoint at the mRNA level, the 3' RACE based Amplification of Papillomavirus Oncogene Transcripts (APOT) assay and Southern blot. Furthermore, the impact of HPV integration on patients' prognosis has been evaluated in a larger set of 186 patients with head and neck cancer. Based on the analysis of E2 mRNA, HPV was integrated in the host genome in 43% of the HPV-positive samples. Extrachromosomal or mixed form was present in 57%. In fresh frozen samples, the APOT and E2 mapping results were in agreement. The results were confirmed using Southern blotting. Furthermore, the type and exact site of integration were determined. The survival analysis of 186 patients revealed HPV positivity, tumour size and lymph node positivity as factors that influence disease specific survival. However, no statistically significant difference was found in disease specific survival between patients with HPV-positive integrated vs. extrachromosomal/mixed forms of the virus.
650    _2
$a Southernův blotting $7 D015139
650    _2
$a spinocelulární karcinom $x virologie $7 D002294
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a nádory hlavy a krku $x mortalita $x virologie $7 D006258
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a infekce papilomavirem $x komplikace $x virologie $7 D030361
650    _2
$a prognóza $7 D011379
650    _2
$a proporcionální rizikové modely $7 D016016
650    _2
$a tonzilární nádory $x virologie $7 D014067
650    _2
$a integrace viru $x genetika $7 D016662
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Sabol, Ivan $u Department of Immunology, Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
700    1_
$a Salakova, Martina $u Department of Immunology, Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
700    1_
$a Turek, Lubomir $u Veterans Affairs Healthcare System and Department of Pathology, University of Iowa, Iowa City, IA.
700    1_
$a Grega, Marek $u Department of Pathology and Molecular Medicine, 2nd Faculty of Medicine, Charles University in Prague, Prague, Czech Republic. $7 xx0209713
700    1_
$a Smahelova, Jana $u Department of Immunology, Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
700    1_
$a Vencalek, Ondrej $u Department of Mathematical Analysis and Applications of Mathematics, Faculty of Science of the Palacky University in Olomouc, Czech Republic.
700    1_
$a Lukesova, Eva $u Department of Immunology, Institute of Hematology and Blood Transfusion, Prague, Czech Republic. Department of Otorhinolaryngology and Head and Neck Surgery, 1st Faculty of Medicine, Charles University in Prague, Motol University Hospital, Prague, Czech Republic.
700    1_
$a Klozar, Jan $u Department of Otorhinolaryngology and Head and Neck Surgery, 1st Faculty of Medicine, Charles University in Prague, Motol University Hospital, Prague, Czech Republic.
700    1_
$a Tachezy, Ruth $u Department of Immunology, Institute of Hematology and Blood Transfusion, Prague, Czech Republic. Department of Genetics and Microbiology, Faculty of Science, Charles University in Prague, Czech Republic.
773    0_
$w MED00002298 $t International journal of cancer $x 1097-0215 $g Roč. 138, č. 2 (2016), s. 386-95
856    41
$u https://pubmed.ncbi.nlm.nih.gov/26239888 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20160722 $b ABA008
991    __
$a 20170111105818 $b ABA008
999    __
$a ok $b bmc $g 1155115 $s 944973
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 138 $c 2 $d 386-95 $e 20150813 $i 1097-0215 $m International journal of cancer $n Int J Cancer $x MED00002298
LZP    __
$a Pubmed-20160722

Najít záznam

Citační ukazatele

Možnosti archivace